Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia
Solomon Shiferaw Nadew aff001; Kidanemariam G/Michael Beyene aff001; Solomon Worku Beza aff002
Působiště autorů: USP/PQM, Addis Ababa, Ethiopia aff001; GAMBYMedical and Business College, Addis Ababa, Ethiopia aff002
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
Adverse drug reactions (ADRs) are global public health problems. In its severe form it may cause hospital admission, morbidity and mortality. Early reporting of suspected ADRs to regulatory authorities is known to be appropriate measure toinsure health and safety of public form such adverse drug reaction of drugs. In Addis Ababa, there is limited information on ADR reporting practices among medical doctors. Hence, this study aimed to assess ADR reporting practices and associated factors among doctors in government hospitals in Addis Ababa.
An institution based cross-sectional mixed-methods study design was used. Data werecollected from 407 doctors using self-administered questionnaire and five key informants using semi-structured questionnaire from October 01 to December 31, 2017. Binary logistic regression and thematic analysis methods for quantitative and qualitative data analysis were used respectively.
Only 94(27.4%) of doctors had ever reported ADRs to national pharmacovigilance center. The study showed that sex (AOR = 3.51, 95% CI: 1.76–7.03), level ofeducation (AOR = 5.01, 95% CI: 2.23–11.28), work experience (AOR = 4.59, 95% CI: 1.21–17.40), existence of ADR reporting form (AOR = 3.96, 95% CI: 1.07–14.61) and reporting to respective marketing authorization holders (AOR = 21.41, 95% CI: 5.89–77.88) were significantly associated with ADR reporting practices. Poor awareness and training on risk of under-reporting, feeling that reporting is minor, absence of appropriate reporting tools, delay and/or absence of feedback on reported ADRs, overly burdened doctors, negligence, fear of legal liabilityand communication gap were cited by key informants as barriers for reporting practice.
Adverse drug reaction reporting practice among doctors wasfound to be low. Sex, level of education, work experience, existence of reporting form and reporting to marketing authorization holderswere significantly associated with ADR reporting practice. In addition, there are gaps in availabilities of guidelines, reporting systems and structure, pre-service and in-service training, and awareness of doctors on impact of reporting. Hence, improving access to ADR reporting form, decentralize safety monitoring system, and conducting awareness training on ADR reporting are essential to improve the ADR reporting practice.
Adverse reactions – Drug safety – Drugs – Ethiopia – Health education and awareness – Medical doctors – Public and occupational health – Qualitative studies
1. FMHACA. Guideline for Adverse Drug Events Monitoring (Pharmacovigilance). 3rd Edition. Addis Ababa, Ethiopia; 2014.
2. WHO. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: World Health Organization; 2004.
3. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Annals of Pharmacotherapy. 2008;42(7–8):1017–25.
4. Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population‐based study of a decade of hospital admissions in New South Wales, Australia. British Journal of Clinical Pharmacology. 2017;83(2):416–26. doi: 10.1111/bcp.13124 27614089
5. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-drug-reaction-related hospitalisations in developed and developing countries: A review of prevalence and contributing factors. Drug Safety. 2016;39(9):847–57. doi: 10.1007/s40264-016-0444-7 27449638
6. Rolfes L, van Hunsel F, Taxis K, van Puijenbroek E. The impact of experiencing adverse drug reactions on the patient’s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Safety. 2016;39(8):769–76. doi: 10.1007/s40264-016-0422-0 27145946
7. WHO. WHO Pharmacovigilance Indicators: A practical manual for the assessment of pharmacovigilance systems. Geneva, Switzerland: World Health Organization; 2015. p. 1–10.
8. Nisa Z, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. Saudi Pharmaceutical Journal. 2018;26(4):453–61. doi: 10.1016/j.jsps.2018.02.014 29844715
9. WHO. Safety monitoring of medical products: reporting system for the general public. Geneva, Switzerland: World Health Organization; 2012. p. 2–8.
10. Khan SA, Goyal C, Chandel N, Rafi M. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. Journal of Natural Science, Biology, and Medicine. 2013;4(1):191–6. doi: 10.4103/0976-9668.107289 23633861
11. Abideen SP. Practical implications of spontaneous adverse drug reaction reporting system in hospitals. Asian Journal Pharmceuticals and Clinical Research. 2013;6(4):10–5.
12. John LJ, Arifulla M, Cheriathu J, Sreedharan J. Reporting of adverse drug reactions: a study among clinicians. Journal of Applied Pharmaceutical Science 2012;2(6):135–59.
13. Iffat W, Shakeel S, Rahim N, Anjum F, Nesar S, Ghayas S. Pakistani physicians’ knowledge and attitude towards reporting adverse drug reactions. African Journal of Pharmacy and Pharmacology. 2014;8(14):379–85.
14. Lemay J, Alsaleh FM, Al-Buresli L, Al-Mutairi M, Abahussain EA, Bayoud T. Reporting of adverse drug reactions in primary care settings in Kuwait: A Comparative study of physicians and pharmacists. International Journal of the Kuwait University, Health Science Centre. 2018;27(1):30–8.
15. Berhe DF, Juhlin K, Star K, Beyene KG, Dheda M, Haaijer-Ruskamp FM, et al. Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase. Tropical Medicine andIinternational Hhealth. 2015;20(6):797–806.
16. Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: Analyses of spontaneous reports in VigiBase®. Drug Safety. 2016;39(4):335–45. doi: 10.1007/s40264-015-0387-4 26754924
17. Sabbleh GT, Akweongo P, Darko D, Dodoo ANO, Sulley AM. Adverse drug reaction reporting by doctors in developing country: A case study from Ghana. Ghana Medical Journal. 2016;48(4):189–93.
18. Abay SM, Dires T. Spontaneous adverse drug reaction reporting and the obstacle in Amhara Region Referral Hospitals, Ethiopia. Pharmacologyonline. 2008.
19. Necho WM, Worku W. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. Journal of Pharmacovigilance. 2014;2:135.
20. Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a crosssectional study. Drug, Healthcare and Patient Safety 2016;8:83–90. doi: 10.2147/DHPS.S116924 27994485
21. Tatiparthi R, Mamo Y. Prevalence of ADRs and associated factors of antiretroviral treatment on HIV positive adults at Jush. Indian Journal of Pharmacy Practice 2014;7(4):8–15.
22. EFMHACA. Guidelines for medicine registration In: 3rd Edition. Addis Ababa, Ethiopia. 2014.
23. WHO. The importance of pharmacovigilance: Safety monitoring of medicinal products. 2002:1–48.
24. Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse drug reaction monitoring in Ethiopia: Analysis of case reports, 2002–2007. Ethiopian Journal of Health Development. 2011;2(168):168–73.
25. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. International Journal of Health Policy and Management. 2015;4(5):295–305. doi: 10.15171/ijhpm.2015.55 25905480
26. Rosli R, Ming LC. A Retrospective analysis of spontaneous adverse drug reactions reports relating to paediatric patients. 2016;11(6):e0155385.
27. UMC. Safetymonitoring of medicinalproducts: Guidelines for setting up and running a pharmacovigilance centre,. the Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring; 2000.
28. CSA. 2007 Population and housing census of Ethiopia: Administrative Report. Addis Ababa: Central Statistical Authority; 2012.
29. Tiruneh MA, Ayele BT. Practice of code of ethics and associated factors among medical doctors in Addis Ababa, Ethiopia. PloS one. 2018;13(8):e0201020. doi: 10.1371/journal.pone.0201020 30089133
30. Beyene KG, Beza SW. Self-medication practice and associated factors among pregnant women in Addis Ababa, Ethiopia. Tropical Medicine and Health. 2018;46:10. doi: 10.1186/s41182-018-0091-z 29743807
31. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code for Biology and Medicine. 2008;3(1):17.
32. Fadare JO, Enwere OO, Afolabi AO, Chedi BAZ, Musa A. Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a Tertiary Centre in Northern Nigeria. Tropical Journal of Pharmaceutical Research. 2011;10(3):235–42.
33. Tew MM, Teoh BC, Mohd Baidi AS, Saw HL. Assessment of knowledge, attitude and practices of adverse drug reaction reporting among doctors and pharmacists in primary healthcare. Advances in Pharmacoepidemiology and Drug Safety. 2016;5(4):1–6.
34. Thomas TM, Udaykumar P, Scandashree K. Knowledge, attitude and practice of adverse drug reaction reporting among doctors in a tertiary health care centre in South India. International Journal of Pharmacology and Clinical Sciences. 2013;2(3):82–8.
35. Ajoy B, Kumar BB, Swapnanil G, Binita S. Knowledge, attitude and practices of pharmacovigilance among junior doctors of a tertiary health care institute in North East India. Scholars Journal of Applied Medical Sciences. 2016;4(9A):3248–53.
36. Stergiopoulos S, Brown CA, Felix T, Grampp G, Getz KA. A Survey of adverse event reporting practices among US healthcare professionals. Drug Safety. 2016;39:1117–27. doi: 10.1007/s40264-016-0455-4 27638657
37. Upadhyaya P, Seth V, Moghe VV, Sharma M, Ahmed M. Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college. Therapeutics and Clinical Risk Management. 2012;8:307–12. doi: 10.2147/TCRM.S31482 22767994
38. Varallo FR, Guimarães SdOP, Abjaude SAR, Mastroianni PdC. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Revista da Escola de Enfermagem da USP. 2014;48(4):739–47.
39. Kamtane RA, Jayawardhani V. Knowledge, Attitude and perception of physicians towards adverse drug reaction (ADR) reporting: A Pharmacoepidemiological Study. Asian Journal Pharmacology and Clinical Research 2012;5(3):210–4.
40. Leone S. 5-year trend of reporting adverse drug reaction: An Italian general practice experience. EC Pharmacology and Toxicology. 2017;5:29–37.
41. Othman GQ, Ibrahim MIM, Alshakka M, Ansari M, Al-Qadasi F, Halboup AM. Knowledge and perception about pharmacovigilance among pharmacy students of Universities in Sana'a Yemen. Journal of Clinical and Diagnostic Research. 2017;11(6):Fc09–fc13. doi: 10.7860/JCDR/2017/24228.10028 28764191
42. Kamal NN, Kamel EG, Mahfouz EM, editors. Adverse drug reactions reporting, knowledge, attitude and practice of physicians towards it in El Minia University Hospitals. International Public Health Forum; 2014;1(4):13–17.
43. Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. African Health Sciences. 2015;15(4):1308–17. doi: 10.4314/ahs.v15i4.34 26958036
44. Ganesan S, Vikneswaran G, Reddy KC, Subrahmanyam DK, Adithan C. A Survey on knowledge, attitude and practice of pharmacovigilance towards adverse drug reactions reporting among doctors and nurses in a tertiary care hospital in South India. Journal of Young Pharmacists. 2016;8(4):471–6.
45. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia.BioMed Research International. 2016;2016:5728462. doi: 10.1155/2016/5728462 28042569
46. Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. Journal of Pharmacology and Pharmacotherapeutics. 2012;3(3):228. doi: 10.4103/0976-500X.99417 23129957
47. Stoynova V, Getov IN, Naseva EK, Lebanova HV, Grigorov EE. Physicians’ knowledge and attitude towards adverse event reporting system and result to intervention–randomized nested trial among Bulgarian physicians. Medicinski Glasnik (Zenica). 2013;10(2):365–72.
Článek vyšel v časopise
2020 Číslo 1
- Aktuální legislativní změny týkající se zdravotnických prostředků – přehledné shrnutí v kostce
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Českým pacientům je nově k dispozici extrakt léčebného konopí. Jaké benefity přináší?
- Od března je hrazena malá molekula slibující velké výsledky hned ve dvou indikacích
- Není statin jako statin aneb praktický přehled rozdílů jednotlivých molekul